Myelin Basic Protein (85-99) Peptide Antagonist (trifluoroacetate salt)

Myelin Basic Protein (85-99) Peptide Antagonist (trifluoroacetate salt)

CAT N°: 36964
Price:

From 43.00 36.55

Myelin basic protein (MBP) (85-99) peptide antagonist is a synthetic peptide that corresponds to residues 85-99 of human MBP and an antagonist of MBP (85-99) with roles in antigen presentation and the autoimmune response.{64665} It inhibits the binding of human MBP (85-99) to human HLA-DR2 in a concentration-dependent manner. MBP (85-99) peptide antagonist inhibits the production of IL-2 in T cell hybridoma cells expressing an MBP (85-99)-specific T cell receptor derived from a patient with multiple sclerosis. It also delays MBP (85-99)-induced experimental autoimmune encephalomyelitis (EAE) onset and reduces EAE symptom severity in double-transgenic humanized mice expressing human HLA-DR2 and MBP (85-99)-specific T cell receptor antigen in a model of multiple sclerosis when administered at a dose of 100 µg/animal.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • L-?-glutamyl-L-lysyl-L-prolyl-L-lysyl-L-valyl-L-?-glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-prolyl-L-alanine, trifluoroacetate salt
  • Correlated keywords
    • 444305-16-2 MBP(85-99) MBP85-99 HLADR2 IL2
  • Product Overview:
    Myelin basic protein (MBP) (85-99) peptide antagonist is a synthetic peptide that corresponds to residues 85-99 of human MBP and an antagonist of MBP (85-99) with roles in antigen presentation and the autoimmune response.{64665} It inhibits the binding of human MBP (85-99) to human HLA-DR2 in a concentration-dependent manner. MBP (85-99) peptide antagonist inhibits the production of IL-2 in T cell hybridoma cells expressing an MBP (85-99)-specific T cell receptor derived from a patient with multiple sclerosis. It also delays MBP (85-99)-induced experimental autoimmune encephalomyelitis (EAE) onset and reduces EAE symptom severity in double-transgenic humanized mice expressing human HLA-DR2 and MBP (85-99)-specific T cell receptor antigen in a model of multiple sclerosis when administered at a dose of 100 µg/animal.

We also advise you